GlassScriptPhysician profile
Edward Korot
NPI 1669853768
$44,275.97
in general payments reported to CMS, 2019-2025
21 companies · $3,058 in 2025
The $3,058 reported for 2025 was more than what 85% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2021: $580 · 2022: $1,451 · 2023: $28K · 2024: $11K · 2025: $3,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Food and Beverage: $5,782 · Honoraria: $1,275 · Travel and Lodging: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,634.50 |
| Food and Beverage | $5,782.37 |
| Honoraria | $1,275.00 |
| Travel and Lodging | $1,232.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $28,814.59 | 2023-2024 | |
| Alimera Sciences, INC. | $4,503.44 | 2021-2024 | Iluvien, Yutiq |
| Regeneron Pharmaceuticals, INC. | $4,273.83 | 2019-2024 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $2,777.51 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $1,242.23 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $1,027.03 | 2021-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $259.89 | 2022-2025 | Vabysmo, Susvimo |
| Coherus Oncology, INC. | $240.47 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $226.71 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $169.11 | 2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Dutch Ophthalmic, USA | $149.47 | 2022 | |
| Genentech, INC. | $143.24 | 2022-2024 | Vabysmo |
| Alcon Vision LLC | $119.40 | 2019 | |
| Allergan, INC. | $114.65 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $50.18 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35.99 | 2025 | Tepezza |
| Abbvie INC. | $34.45 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.44 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.94 | 2024 | Acthar |
| Oyster Point Pharma, INC. | $21.86 | 2023 | Tyrvaya |
| Horizon Therapeutics Plc | $21.54 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Korot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.